Tarsus Pharmaceuticals, Inc.
TARS · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | $183 | $17 | $26 | $57 |
| % Growth | 948.6% | -32.4% | -54.7% | – |
| Cost of Goods Sold | $13 | $2 | $1 | $2 |
| Gross Profit | $170 | $16 | $25 | $55 |
| % Margin | 93% | 90.9% | 96.3% | 96.4% |
| R&D Expenses | $53 | $50 | $43 | $42 |
| G&A Expenses | $0 | $0 | $45 | $25 |
| SG&A Expenses | $237 | $109 | $45 | $25 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $291 | $159 | $88 | $67 |
| Operating Income | -$121 | -$143 | -$63 | -$12 |
| % Margin | -65.9% | -820.5% | -242.9% | -21.3% |
| Other Income/Exp. Net | $5 | $7 | $1 | -$2 |
| Pre-Tax Income | -$116 | -$136 | -$62 | -$14 |
| Tax Expense | $0 | $0 | -$0 | $0 |
| Net Income | -$116 | -$136 | -$62 | -$14 |
| % Margin | -63.2% | -778.9% | -240.5% | -24.2% |
| EPS | -3.07 | -4.62 | -2.52 | -0.67 |
| % Growth | 33.5% | -83.3% | -276.1% | – |
| EPS Diluted | -3.07 | -4.62 | -2.52 | -0.67 |
| Weighted Avg Shares Out | 38 | 29 | 25 | 21 |
| Weighted Avg Shares Out Dil | 38 | 29 | 25 | 21 |
| Supplemental Information | – | – | – | – |
| Interest Income | $15 | $10 | $3 | $0 |
| Interest Expense | $7 | $3 | $2 | $0 |
| Depreciation & Amortization | $1 | $1 | $0 | $0 |
| EBITDA | -$106 | -$132 | -$60 | -$13 |
| % Margin | -58.2% | -754.7% | -231.3% | -23.6% |